ライフサイエンスコーパス: underpowered

1 ion analysis can be performed, it is grossly underpowered.

2 x (triglyceride : HDL-C ratio), or have been underpowered.

3 ints but may have had selection bias or been underpowered.

4 tudies using Froh to date have probably been underpowered.

5 d sample sizes suggest that cGxE studies are underpowered.

6 described in several studies, but many were underpowered.

7 c hepatitis B infection, but the trials were underpowered.

8 ancreatitis, although the study was probably underpowered.

9 xpected event rates, the trial may have been underpowered.

10 ted and (2) studies that are not aborted are underpowered.

11 tive cisplatin-based regimens, but they were underpowered.

12 power and, consequently, in studies that are underpowered.

13 bject to high sample variance, and therefore underpowered.

14 ated in SZ because of previous studies being underpowered.

15 gnificance; however, the study may have been underpowered.

16 The subgroup analysis by sex was underpowered.

17 inconsistent results, and some analyses were underpowered.

18 cally heterogeneous, and some were small and underpowered.

19 erence of networks in this setting is highly underpowered.

20 t that analysing individual rare variants is underpowered.

21 otential risk, although the study of RV1 was underpowered.

22 tain extent of information loss and thus are underpowered.

23 ected, which may have caused the study to be underpowered.

24 nature, initial genetic studies were mostly underpowered.

25 asets of delayed antibiotic prescription are underpowered.

26 ome diagnostic tools are most inaccurate and underpowered.

27 emonstrate benefit, likely because they were underpowered.

28 for multiple testing, but this analysis was underpowered.

29 , results have been contradictory and trials underpowered.

30 n CC size; however, the studies were heavily underpowered (20% power to detect Cohen's d = .3).

31 ts were classified in 4 mismatch categories: underpowered (29%), overpowered (32%), underpowered/over

32 genome-wide association study data are often underpowered after adjustment for multiple comparisons.

33 ant clinical benefit, although the study was underpowered and alternative results cannot be excluded.

34 These studies have largely been underpowered and contradictory.

35 However, most studies have been underpowered and demonstrate elements of a statistical '

36 tudy, can result in a clinical trial that is underpowered and fails to detect a truly effective new t

37 rugs to treat symptoms of MS have often been underpowered and have used inappropriate measures of out

38 Nevertheless, our study was underpowered and important differences between groups ma

39 Three trials were underpowered and of insufficient duration to evaluate sc

40 suggested, but some of these approaches are underpowered and result in high false positive rates bec

41 Our epidemiological study was underpowered and retrospective in nature, so firm conclu

42 is that intranasal OT studies are generally underpowered and that there is a high probability that m

43 However, the study was underpowered and the confidence intervals were wide.

44 nt chemotherapy for bladder cancer have been underpowered and/or terminated prematurely, yielding inc

45 However, the trial may be underpowered, and an interaction was found between longe

46 uman intervention studies have been limited, underpowered, and not well controlled.

47 Because sample sizes left most studies underpowered, and procedures to enhance treatment fideli

48 as been complicated by phenotypic diversity, underpowered association studies and ancestry-specific e

49 However, the study was underpowered because it did not meet the planned accrual

50 The planned non-inferiority test was underpowered because of the low number of events.

51 sis in children aged 12 months and older was underpowered because there were few unvaccinated cases a

52 Its heterogeneity and rarity often result in underpowered clinical trials making the analysis and int

53 has been complicated by conflicting results, underpowered clinical trials, and the lack of a placebo

54 te long-standing critiques of the conduct of underpowered clinical trials, the practice not only rema

55 guments to support the validity and value of underpowered clinical trials: that meta-analysis may "sa

56 conducted at a single site and was slightly underpowered compared with the initial design.

57 g patients with fixed EDSS of >/=6.0 will be underpowered even with large numbers or prolonged durati

58 These calculations were derived from a small underpowered experimental data set for the fungus and tw

59 e sizes and hence power, since the currently underpowered experiments in preclinical biomedicine are

60 d with bisphosphonate use, but the study was underpowered for definitive conclusions.

61 oach for detecting common variants, they are underpowered for detecting associations with rare varian

62 existing single-marker association tests are underpowered for detecting rare risk variants.

63 Because of early closure, this study is underpowered for drawing conclusions about the impact on

64 This study was severely underpowered for its primary endpoint, and therefore no

65 Comparative studies have been underpowered for mortality because of small sample size.

66 or harms with fewer prenatal visits but was underpowered for rare, serious outcomes.

67 ity definition at 2 of 9 time points but was underpowered for the observed treatment effect.

68 he intended sample size, leaving it severely underpowered for the primary composite endpoint of death

69 ut our sample, the largest yet reported, was underpowered for their detection.

70 Randomized controlled trials (RCT) are often underpowered for validating gene-treatment interactions.

71 The studies meta-analyzed were generally underpowered; however, the number of statistically signi

72 hods, however, use a single distance and are underpowered if the distance is poorly chosen.

73 tected many common causal variants, they are underpowered in identifying disease variants that are to

74 , the notion that studies are systematically underpowered is not the full story: low power is far fro

75 se of their relatively small sample sizes or underpowered methodologies.

76 Although the study was underpowered, no adverse effects were observed.

77 The one-sided 95% CI for the underpowered non-inferiority test on the hazard ratio wa

78 terol (TC) concentration have been small and underpowered: not surprisingly, the findings have been i

79 886 meta-analyses, all included studies were underpowered; only 2,588 (17%) included at least two ade

80 been tested in numerous phase II studies and underpowered or flawed phase III studies.

81 ped to correct for the bias, they are either underpowered or theoretically invalid.

82 However, studies are contradictory, underpowered, or do not control for confounders.

83 ries: underpowered (29%), overpowered (32%), underpowered/overpowered (32%), and unrelated (3%).

84 neutral results might be because COSSACS was underpowered owing to early termination of the trial, an

85 y, we report possible reasons that cause the underpowered phenomenon and show how the power of the VC

86 Available evidence, from underpowered pooled data, neither supports nor refutes a

87 ere found in any of the other comparisons in underpowered RCT data.

88 and the end of funding, which left the study underpowered relative to its primary study end point.

89 longitudinal feature of the data, leading to underpowered results and less biologically meaningful re

90 east two adequately powered and at least one underpowered, results were compared with and without und

91 neuroscience: on average, studies are indeed underpowered-some very seriously so-but many studies sho

92 So far, only three small, underpowered studies and one single-centre trial have be

93 e fact that initially exciting findings from underpowered studies are so often not replicated in larg

94 relative influence of adequately powered and underpowered studies in published meta-analyses has not

95 However, underpowered studies made up the entirety of the evidenc

96 meta-analyses reported by Cochrane reviews, underpowered studies often contribute little information

97 hrane reviews, and investigate the impact of underpowered studies on meta-analysis results.

98 onsider whether it will solve the problem of underpowered studies or whether it is another affliction

99 e of replication; for these, false negative, underpowered studies probably contribute to inconsistent

100 In the subset examined, odds ratios in underpowered studies were 15% lower (95% CI 11% to 18%,

101 f 11% (inter-quartile range -1% to 35%) when underpowered studies were omitted; and between-study het

102 attributed to the fallacies that arise from underpowered studies, resulting in overly optimistic or

103 stablish the presence of a genetic signal in underpowered studies, to infer the genetic architecture

104 magnetic resonance imaging (MRI) have led to underpowered studies.

105 ypes in genetic searches and the reliance on underpowered studies.

106 RQoL to be undermined by poorly designed and underpowered studies.

107 erate or high amounts can result in severely underpowered studies.

108 ered, results were compared with and without underpowered studies.

109 cacy of OPBS is based on poorly designed and underpowered studies.

110 In this early, underpowered study evaluating treatments for neovascular

111 had a higher QoL than did Caucasians in this underpowered study that used self-reported dietary data.

112 However, the trial was underpowered to address the effect of routine induction

113 randomized controlled trials on weaning are underpowered to address this issue.

114 een studied, and most studies conducted were underpowered to allow definitive conclusions.

115 Study was underpowered to conclusively validate the efficacy, but

116 imited value due to poor recruitment and are underpowered to definitively answer these questions.

117 n the recipient (OR=0.46), but the study was underpowered to demonstrate this unforeseen effect (P=0.

118 analysis, although this latter analysis was underpowered to detect a causal effect of BMI on HIF3A m

119 two disorders, although the sample is likely underpowered to detect a modest shared signal.

120 The study may have been underpowered to detect a significant difference in incid

121 e probability that the study might have been underpowered to detect a significant reduction in mortal

122 h in this study, the trial was substantially underpowered to detect a statistically significant morta

123 l outcomes at 1 year; however, the study was underpowered to detect a treatment effect.

124 infection or disease, although the study was underpowered to detect an effect against disease.

125 of randomised trials is sparse and they are underpowered to detect any meaningful difference.

126 ty variants, although most studies have been underpowered to detect associations of a realistic magni

127 As single variant testing is underpowered to detect associations, the development of

128 WAS) of HIV-1-infected populations have been underpowered to detect common variants with moderate imp

129 s currently available, this approach remains underpowered to detect drivers, particularly in less stu

130 the active form of vitamin D, the study was underpowered to detect effects smaller than an OR of 1.3

131 ority of COPD candidate gene era studies are underpowered to detect genetic effect odds ratios of 1.2

132 gh prevalence means that the sample is still underpowered to detect genetic effects typical for compl

133 ple size for the genetic analysis, which was underpowered to detect genome-wide significance, the eva

134 Given that our sample size was underpowered to detect genome-wide significance, we appl

135 Studies can be underpowered to detect improvement with chemotherapy as

136 Furthermore, these studies were generally underpowered to detect meaningful clinical difference or

137 ry, most COPD candidate gene era studies are underpowered to detect moderate-sized genetic effects.

138 The trial was therefore underpowered to detect significant differences in mortal

139 However, the study was underpowered to detect significant differences in safety

140 bserved survival differences, CALGB 9633 was underpowered to detect small but clinically meaningful i

141 Although still underpowered to detect small differences for infrequent

142 tween the two groups, although the trial was underpowered to detect such differences.

143 , Bonferroni-derived thresholds are severely underpowered to detect the vast majority of associations

144 disorder, but previous studies may have been underpowered to detect these effects.

145 The study was underpowered to detect treatment effect of ACE inhibitor

146 They were also underpowered to disentangle genetic from environmental f

147 rtant, and it is possible that the study was underpowered to establish statistical significance.

148 Previous studies, underpowered to examine hospital admission, have found a

149 actor for predicting CVD, but they have been underpowered to examine whether this is true for differe

150 ath by suicide separately, but the study was underpowered to explore familial liability for this asso

151 This study may have been underpowered to identify a significant difference.

152 However, the study may have been underpowered to identify an early clinically important d

153 imited by their single-center design and are underpowered to identify risk factors for serious advers

154 However, the BMS subset may have been underpowered to identify such differences, and further t

155 i, the majority of studies are statistically underpowered to isolate the many contributing variants,

156 nia or mood disorders, although the study is underpowered to observe rare events.

157 Due to a high withdrawal rate, the study was underpowered to prove a difference in BOS-free survival.

158 sult, all three trials will be substantially underpowered to test the specific hypotheses of total ho

159 We conclude that underpowered trials are ethical in only 2 situations: sm

160 So-called underpowered trials might be acceptable if investigators

161 s that are owed to potential participants in underpowered trials so they may make autonomous enrollme

162 moral issues associated with the conduct of underpowered trials, the disclosures that are owed to po

163 uture meta-analyses may justify individually underpowered trials.

164 ed model methods may be poorly calibrated or underpowered under family sampling bias and/or case-cont

165 Individual studies will remain underpowered unless sample size is increased or improvem

166 onomic and political traits are dramatically underpowered, which implies a high false discovery rate.

167 Many subgroup analyses were underpowered, which may have resulted in false-negative

168 of which were retrospective cohort studies, underpowered with no significant differences in survival